Flutter Over Debut Of Glenmark's Favipiravir For COVID-19 In India
Poised For Scale-Up Using In-House Capabilities
Glenmark has received the go-ahead in India for its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process. While the firm says trial findings are in line with global data, with patients showing clinical improvements within the first seven days, social media is abuzz, with some physicians seeking greater clarity.
You may also be interested in...
Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.
Glenmark's Phase III trial of the antiviral points to efficacy in mild-to-moderate COVID-19, but many physicians in India remain skeptical.
Executives from Moderna, Pfizer and AstraZeneca and others will give politicians in Washington DC an update on the progress of their vaccine - but will resist pressure to make promises of a breakthrough in 2020.